PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSunitinib malate
Sunitinib malate
Sunitinib, Sutent (sunitinib malate) is a small molecule pharmaceutical. Sunitinib malate was first approved as Sutent on 2006-01-26. It is used to treat gastrointestinal stromal tumors, neuroendocrine tumors, pancreatic neoplasms, and renal cell carcinoma in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors, neuroendocrine tumors, and renal cell carcinoma.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
sunitinib malateANDA2024-09-10
sutentNew Drug Application2022-12-08
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EX: Other protein kinase inhibitors in atc
— L01EX01: Sunitinib
HCPCS
No data
Clinical
Clinical Trials
586 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292EFO_0000376—319829770224
CarcinomaD002277—C80.0259527544186
NeoplasmsD009369—C803527411781
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A15321222077
Breast neoplasmsD001943EFO_0003869C50122141335
Non-small-cell lung carcinomaD002289——41321120
Neuroendocrine tumorsD018358EFO_1001901D3A.83811619
Thyroid neoplasmsD013964EFO_0003841——6—129
Islet cell adenomaD007516EFO_0007331D13.7231129
Ovarian neoplasmsD010051EFO_0003893C56—7—1—8
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney neoplasmsD007680EFO_0003865C647335—1761
Lung neoplasmsD008175HP_0100526C34.902212—126
Prostatic neoplasmsD011471—C615131—118
RecurrenceD012008——3121—217
Colorectal neoplasmsD015179——492—215
Pancreatic neoplasmsD010190EFO_0003860C25382—114
Liver neoplasmsD008113EFO_1001513C22.02102—214
Neoplasm metastasisD009362EFO_0009708—271—312
GlioblastomaD005909EFO_0000515—571——12
Stomach neoplasmsD013274EFO_0003897C16451—111
Show 11 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749—C67114———14
MelanomaD008545——312———13
SarcomaD012509——49———11
Transitional cell carcinomaD002295———10———10
AdenocarcinomaD000230——18———9
LeukemiaD007938—C9534——18
LymphomaD008223—C85.934——18
Myeloid leukemia acuteD015470—C92.043——17
Myeloid leukemiaD007951—C9243——17
Lymphoid leukemiaD007945—C9133——17
Show 132 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Castration-resistant prostatic neoplasmsD064129——1———12
Myeloproliferative disordersD009196—D47.12————2
Hodgkin diseaseD006689—C812————2
Myelodysplastic-myeloproliferative diseasesD054437——2————2
ThrombocytosisD013922HP_0001894D75.832————2
Mantle-cell lymphomaD020522——1———12
AnemiaD000740HP_0001903D64.91————1
Wet macular degenerationD057135EFO_0004683—1————1
Hand-foot syndromeD060831EFO_1001893—1————1
Tongue neoplasmsD014062EFO_0003871C02.91————1
Show 46 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10————55
CardiotoxicityD066126EFO_1001482—————44
FatigueD005221HP_0012378R53.83————44
Torsades de pointesD016171EFO_0005307I47.21————22
Mouth neoplasmsD009062EFO_0003868C06.9————22
Heart failureD006333HP_0001635I50————22
Acute diseaseD000208——————11
Long qt syndromeD008133HP_0001657I45.81————11
DeliriumD003693—R41.0————11
Renal insufficiencyD051437HP_0000083N19————11
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSunitinib malate
INNsunitinib
Description
Sunitinib is a member of pyrroles and a monocarboxylic acid amide. It has a role as an angiogenesis inhibitor, an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a vascular endothelial growth factor receptor antagonist, an immunomodulator and a neuroprotective agent. It is functionally related to a 3-methyleneoxindole.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Identifiers
PDB—
CAS-ID557795-19-4
RxCUI357977
ChEMBL IDCHEMBL1567
ChEBI ID—
PubChem CID5329102
DrugBankDB01268
UNII IDV99T50803M (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Sutent – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 36,225 documents
View more details
Safety
Black-box Warning
Black-box warning for: Sunitinib malate, Sutent
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
49,569 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use